**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a single centre retrospective study of 15 patients, 13 patients (10 men and 3 women) aged 22−65 years were described, who developed various toxicities following treatment with immunosuppressants \[*not all routes and dosages stated; durations of treatments to reactions onsets not stated*\].

Case 2: A 51-year-old man developed Epstein-Barr virus and post-transplantation lymphoproliferative disorder following treatment with fludarabine, ciclosporin, mycophenolate mofetil, prednisolone and etanercept \[Enbrel\]. The man, who had non-Hodgkin lymphoma, was scheduled for allogeneic stem cell transplantation. He then received non-myeloablative conditioning therapy with fludarabine 3 x 30 mg/m^2^along with total body irradiation. Thereafter, he underwent allogeneic stem cell transplantation (allo-SCT). He received graft versus host disease (GVHD) prophylaxis with ciclosporin and mycophenolate mofetil. Despite the prophylaxis, he developed acute GVHD with an involvement of liver and gut 27 days after allo-SCT. For the treatment of acute GVHD, he received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. However, he developed steroid-refractory acute GVHD. Thirty days after the discontinuation of first line therapy, he received second-line treatment with SC etanercept 25 mg twice weekly for steroid-refractory acute GVHD. Subsequently, he developed Epstein-Barr virus and post-transplantation lymphoproliferative disorder. He died due to GVHD.

Case 3: A 57-year-old woman developed cytomegalovirus reactivation and sepsis of unknown origin following treatment with fludarabine, ciclosporin, prednisolone and etanercept \[Enbrel\]. The woman, who had acute myeloid leukaemia, was scheduled for allogeneic stem cell transplantation. She then received non-myeloablative conditioning therapy with fludarabine 3 x 30 mg/m^2^ along with total body irradiation. Thereafter, she underwent allogeneic stem cell transplantation. She did not receive graft versus host disease (GVHD) prophylaxis. She developed acute GVHD with an involvement of gut 357 days after allo-SCT. For the treatment of acute GVHD, she received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. However, she developed steroid-refractory acute GVHD. Nine days after the discontinuation of first line therapy, she received a second line therapy with SC etanercept 25mg twice weekly for steroid-refractory acute GVHD. Subsequently, she developed cytomegalovirus reactivation and sepsis of unknown origin. She died due to GVHD.

Case 4: A 60-year-old man developed Epstein-Barr virus reactivation following treatment with fludarabine, ciclosporin, mycophenolate mofetil, prednisolone and etanercept \[Enbrel\]. The man, who had chronic lymphatic leukaemia, was planned for allogeneic stem cell transplantation. He then received non-myeloablative conditioning therapy with fludarabine 3 x 30 mg/m^2^ along with total body irradiation. Thereafter, he underwent allogeneic stem cell transplantation. He received graft versus host disease (GVHD) prophylaxis with ciclosporin and mycophenolate mofetil. Despite the prophylaxis, he developed acute GVHD with an involvement of gut 84 days after allo-SCT. For the treatment of acute GVHD, he received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. However, he developed steroid-refractory acute GVHD. Twenty-four days after the discontinuation of first line therapy, he received SC etanercept 25mg twice weekly for steroid-refractory acute GVHD. Subsequently, he developed Epstein-Barr virus reactivation. He died due to GVHD.

Case 5: A 53-year-old woman died due to cytomegalovirus reactivation, pulmonary aspergillosis and anal herpes simplex lesion following treatment with cyclophosphamide, fludarabine, ciclosporin, prednisolone and etanercept \[Enbrel\]. The woman, who had acute lymphoblastic leukaemia, was planned for allogeneic stem cell transplantation. She then received reduced intensity conditioning therapy with cyclophosphamide 1 x 60 mg/kg and fludarabine 4 x 40 mg/m^2^ along with total body irradiation. Thereafter, she underwent allogeneic stem cell transplantation (Allo-SCT). She received graft versus host disease (GVHD) prophylaxis with ciclosporin. Despite the prophylaxis, she developed acute GVHD with an involvement of gut and liver 50 days after the allo-SCT. For the treatment of acute GVHD, she received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. However, she developed steroid-refractory acute GVHD. Twenty four days after the discontinuation of first line therapy, she received SC etanercept 25mg twice weekly for steroid-refractory acute GVHD. Subsequently, she developed CMV reactivation, pulmonary aspergillosis and anal herpes simplex lesion. Eventually, she died due to cytomegalovirus reactivation, pulmonary aspergillosis and anal herpes simplex lesion.

Case 6: A 59-year-old man died due to BK virus cystitis and *Escherichia coli*sepsis following treatment with cyclophosphamide, fludarabine, ciclosporin, prednisolone and etanercept \[Enbrel\]. The man, who had myeloproliferative disease, was planned for allogeneic stem cell transplantation. He then received reduced intensity conditioning therapy with cyclophosphamide 1 x 60 mg/kg and fludarabine 4 x 40 mg/m^2^ along with total body irradiation. Thereafter, he underwent allogeneic stem cell transplantation (Allo-SCT). He received graft versus host disease (GVHD) prophylaxis with ciclosporin. Despite the prophylaxis, he developed acute GVHD with an involvement of skin and gut 23 days after allo-SCT. For the treatment of acute GVHD, he received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. However, he developed steroid-refractory acute GVHD. Eleven days after the discontinuation of first line therapy, he received SC etanercept 25mg twice weekly for steroid-refractory acute GVHD. Subsequently, he died due to the BK virus cystitis and *Escherichia coli*sepsis.

Case 7: A 60-year-old man died due to *Enterococcus faecium*sepsis following treatment with fludarabine, ciclosporin, mycophenolate mofetil, prednisolone and etanercept \[Enbrel\]. The man, who had myelodysplastic syndrome, was planned for allogeneic stem cell transplantation. He then received non-myeloablative conditioning therapy with fludarabine 3 x 30 mg/m^2^ along with total body irradiation. Thereafter, he underwent allogeneic stem cell transplantation (Allo-SCT). He received graft versus host disease (GVHD) prophylaxis with ciclosporin and mycophenolate mofetil. Despite the prophylaxis, he developed acute GVHD with an involvement of skin and gut 61 days after allo-SCT. Therefore, he received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. However, he developed steroid-refractory acute GVHD. Nine days after the discontinuation of the first line therapy, he received SC etanercept twice weekly 25mg for steroid-refractory acute GVHD. Subsequently, he died due to *Enterococcus faecium* sepsis.

Case 8: A 39-year-old woman died due to Epstein-Barr virus reactivation following treatment with cyclophosphamide, ciclosporin, mycophenolate mofetil, prednisolone and etanercept \[Enbrel\]. The woman, who had acute myeloid leukaemia, was planned for allogeneic stem cell transplantation. She then received myeloablative conditioning therapy with cyclophosphamide 2 x 60 mg/kg along with total body irradiation. Thereafter, she underwent allogeneic stem cell transplantation (Allo-SCT). She received graft versus host disease (GVHD) prophylaxis with ciclosporin and mycophenolate mofetil. Despite the prophylaxis, she developed acute GVHD with an involvement of liver and gut 27 days after allo-SCT and therefore she received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. However, she developed steroid-refractory acute GVHD. Twenty days after the discontinuation of the first line therapy, she received SC etanercept 25mg twice weekly for steroid-refractory acute GVHD. Subsequently, she died due to Epstein-Barr virus reactivation.

Case 9: A 55-year-old man developed *Bacteroides fragilis* sepsis and cytomegalovirus colitis following treatment with cyclophosphamide, fludarabine, ciclosporin, mycophenolate mofetil, prednisolone and etanercept \[Enbrel\]. The man, who had myeloproliferative disease, was planned for allogeneic stem cell transplantation. He then received reduced intensity conditioning therapy with cyclophosphamide 1 x 60 mg/kg and fludarabine 4 x 40 mg/m^2^ along with total body irradiation. Thereafter, he underwent allogeneic stem cell transplantation (Allo-SCT). He received graft versus host disease (GVHD) prophylaxis with ciclosporin and mycophenolate mofetil. Despite the prophylaxis, he developed acute GVHD with an involvement of gut 126 days after allo-SCT and therefore he received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. However, he developed steroid-refractory acute GVHD. Thirty-six days after the discontinuation of first line therapy, he received SC etanercept 25mg twice weekly. Subsequently, he developed *Bacteroides fragilis* sepsis and cytomegalovirus colitis. He died due to GVHD.

Case 10: A 65-year-old man developed *Escherichia coli*sepsis following treatment with cyclophosphamide, fludarabine, ciclosporin, mycophenolate mofetil, prednisolone and etanercept \[Enbrel\]. The man, who had acute myeloid leukaemia, was planned for allogeneic stem cell transplantation. He then received reduced intensity conditioning therapy with cyclophosphamide 1 x 60 mg/kg and fludarabine 4 x 40 mg/m^2^ along with total body irradiation. Thereafter, he underwent allogeneic stem cell transplantation (Allo-SCT). He received graft versus host disease (GVHD) prophylaxis with ciclosporin and mycophenolate mofetil. Despite the prophylaxis, he developed acute GVHD with an involvement of gut 39 days after allo-SCT and therefore he received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. However, he developed steroid-refractory acute GVHD. Five days after the discontinuation of the first line therapy, he received SC etanercept 25mg twice weekly. Following the treatment, he developed *Escherichia coli* sepsis. He died due to GVHD.

Case 11: A 54-year-old man developed CNS catheter-related sepsis and cellulitis following treatment with fludarabine, mycophenolate mofetil, ciclosporin, prednisolone and etanercept \[Enbrel\]. The man, who had non-Hodgkin lymphoma, was planned for allogeneic stem cell transplantation. He then received non-myeloablative conditioning therapy with fludarabine 3 x 30 mg/m^2^ along with total body irradiation. Thereafter, he underwent allogeneic stem cell transplantation (Allo-SCT). He received graft versus host disease (GVHD) prophylaxis with mycophenolate mofetil. Despite the prophylaxis, he developed acute GVHD with an involvement of liver and gut 393 days after allo-SCT and therefore he received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. However, he developed steroid-refractory acute GVHD. Thirteen days after the discontinuation of first line therapy, he received SC etanercept 25mg twice weekly. Subsequently, he developed CNS catheter-related sepsis and cellulitis. He died due to GVHD.

Case 12: A 52-year-old man developed *Klebsiella pneumoniae*sepsis following treatment with cyclophosphamide, fludarabine, ciclosporin, mycophenolate mofetil, prednisolone and etanercept \[Enbrel\]. The man, who had non-Hodgkin lymphoma, was planned for allogeneic stem cell transplantation. He then received reduced intensity conditioning therapy with cyclophosphamide 1 x 60 mg/kg and fludarabine 4 x 40 mg/m^2^ along with total body irradiation. Thereafter, he underwent allogeneic stem cell transplantation (Allo-SCT). He received graft versus host disease (GVHD) prophylaxis with ciclosporin. Despite the prophylaxis, he developed acute GVHD with an involvement of gut 79 days after allo-SCT and therefore he received first line therapy with mycophenolate mofetil and prednisolone 2 mg/kg/day. However, he developed steroid-refractory acute GVHD. Twenty-eight days after the discontinuation of first line therapy, he received SC etanercept 25mg twice weekly. Subsequently, he developed *Klebsiella pneumoniae*sepsis. He died due to cardiac arrest.

Case 13: A 53-year-old man died due to pulmonary aspergillosis, zygomycosis, rhinovirus and*Enterococcus faecium* sepsis following treatment with fludarabine, ciclosporin, mycophenolate mofetil, prednisolone and etanercept \[Enbrel\]. The man, who had T-cell prolymphocytic leukaemia, was scheduled for allogeneic stem cell transplantation. He then received non-myeloablative conditioning therapy with fludarabine 3 x 30 mg/m^2^ along with total body irradiation. Thereafter, he underwent allogeneic stem cell transplantation (Allo-SCT). He received graft versus host disease (GVHD) prophylaxis with ciclosporin and mycophenolate mofetil. Despite the prophylaxis, he developed acute GVHD with an involvement of skin and gut 41 days after allo-SCT and therefore he received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. He then developed steroid-refractory acute GVHD. Nineteen days after the discontinuation of first line therapy, he received SC etanercept 25mg twice weekly. Subsequently, he died due to pulmonary aspergillosis, zygomycosis, rhinovirus and *Enterococcus faecium* sepsis.

Case 14: A 22-year-old man died due to disseminated aspergillosis, cytomegalovirus reactivation and pulmonary infection (rhino/coronavirus and *Citrobacter freundii*) following treatment with fludarabine, prednisolone, mycophenolate mofetil, ciclosporin and etanercept \[Enbrel\]. The man, who had Hodgkin lymphoma, was planned for allogeneic stem cell transplantation. He received non-myeloablative conditioning therapy with fludarabine 3 x 30 mg/m^2^ along with total body irradiation. Thereafter, he underwent allogeneic stem cell transplantation (Allo-SCT). He received graft versus host disease (GVHD) prophylaxis with prednisolone and mycophenolate mofetil. Despite the prophylaxis, he developed acute GVHD with an involvement of gut and liver 86 days after allo-SCT and therefore he received first line therapy with ciclosporin and prednisolone 2 mg/kg/day. He then developed steroid-refractory acute GVHD. Twelve days after the discontinuation of first line therapy, he received SC etanercept 25mg twice weekly. Subsequently, he died of disseminated aspergillosis, cytomegalovirus reactivation and pulmonary infection (rhino/coronavirus and *Citrobacter freundii*).

**Author comment:** *\"We report infectious complications in 81.3% of the patients.\" \"In 40% of patients, death was attributable to an infectious complication.\" \"The risk of opportunistic infections is known to be high in \[steroid refractory-graft versus host disease\], due to the strong immunosuppressive regimen imposed on a frail, recovering post-transplant immune system.\" \"\[Etanercept\], in particular, are associated with a high incidence of opportunistic infections.\"*
